CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial
about
Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatmentPegylated liposomal doxorubicin for relapsed epithelial ovarian cancerImproving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies.CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery.The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancerCA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review.Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach.Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?Serum CA125, CA199 and CEA Combined Detection for Epithelial Ovarian Cancer Diagnosis: A Meta-analysis.
P2860
Q24193738-7965E05F-D5B5-4452-886F-60EEDD101ABEQ24201282-AD934311-9B4D-43DC-83B7-BD1F1A3853F7Q34306120-AFEFEBAA-23AC-4164-822A-569E3D85A524Q36621252-2C1C4C81-B91E-432B-B332-93FA44923AB0Q37022524-4C5047D2-6F50-4FC8-BE40-1B970DAA1E02Q38627394-388CC632-B5D9-4D56-81EA-97A6CA114B63Q39608246-D21633C8-B2E6-41C3-B490-6D2F653C5C77Q40197234-B18F99F3-130F-4350-8605-46A3305D52ECQ47111053-38503C13-F72B-42F6-A816-7B27D068787DQ50857141-427D6F62-5835-4687-BF09-26B67CA46338Q55004891-EE897558-D08D-4713-8171-E80CF4B55123
P2860
CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
CA-125 can be part of the tumo ...... ence of the GCIG CALYPSO trial
@ast
CA-125 can be part of the tumo ...... ence of the GCIG CALYPSO trial
@en
type
label
CA-125 can be part of the tumo ...... ence of the GCIG CALYPSO trial
@ast
CA-125 can be part of the tumo ...... ence of the GCIG CALYPSO trial
@en
prefLabel
CA-125 can be part of the tumo ...... ence of the GCIG CALYPSO trial
@ast
CA-125 can be part of the tumo ...... ence of the GCIG CALYPSO trial
@en
P2093
P2860
P356
P1476
CA-125 can be part of the tumo ...... ence of the GCIG CALYPSO trial
@en
P2093
B Fitzharris
E Pujade-Lauraine
H Chalchal
J Alexandre
P2860
P2888
P304
P356
10.1038/BJC.2011.593
P407
P50
P577
2012-01-12T00:00:00Z